TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06959615: A Multicenter, Open Phase I/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration

Sponsor: Jacobio Pharmaceuticals Co., Ltd. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 334 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,835,750

Rescue Site Savings

+$5,811,960

Unlock Full NCT06959615 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06959615 Rescue Dossier →